Preventing respiratory syncytial virus infections in hospitalized children and adults: should we do better?

Pierre Frangea,b,*, Julie Toubianac,d, Perrine Parizee, Florence Moulinf, Anne Scemlag,h, Marianne Leruez-Villea,b,i

a Laboratoire de Microbiologie Clinique, Assistance Publique — Hôpitaux de Paris (AP-HP), Hôpital Necker — Enfants Malades, Paris, France
b Institut Imagine, Université de Paris, EHU 7327, Paris, France
c Université de Paris, Service de Pédiatrie Générale et Maladies Infectieuses, AP-HP, Hôpital Necker — Enfants Malades, Paris, France
d CNR de la Coqueluche et Autres Bordetelloises, Unité « Biodiversité et épidémiologie des Bactéries Pathogènes », Institut Pasteur, Paris, France
e Université Paris Descartes, Centre d’Infectiologie Necker-Pasteur, IHU Imagine, AP-HP, Hôpital Necker — Enfants Malades, Paris, France
f Service de Réanimation et Surveillance Continue Médico-chirurgicale Pédiatrique, AP-HP, Hôpital Necker Enfants-Malades, Paris, France
g Service de Nephrologie — Transplantation, AP-HP, Hôpital Necker-Enfants Malades, Paris, France
h RTRS Centaure, Labex Transplantex, Université de Paris, Paris, France
i CNR Cytomegalovirus, Laboratoire Associé, 149 Rue de Sèvres, 75015, Paris, France

SUMMARY

Objective: To compare the burden of nosocomial and community-acquired respiratory syncytial virus (RSV)-associated acute lower respiratory tract infections (ALRIs) in adult and pediatric patients concomitantly admitted to a French tertiary hospital, and to evaluate the effectiveness of existing infection control measures.

Patients and methods: We prospectively included all adult and pediatric patients admitted to Necker hospital (Paris) between October 2018 and February 2019 with a diagnosis of RSV-associated ALRI. We compared characteristics of ALRIs between patients with community-acquired versus nosocomial infections and, in each group, between children and adults.

Results: Community-acquired and nosocomial RSV-associated ALRIs were diagnosed in 229 and 11 inpatients, respectively. The burden of community-acquired infections was higher in children than in adults: 2.1% versus 0.2% of the total number of pediatric and adult inpatients, respectively (p < 0.0001); 4.2% versus 0.2% of the total number of hospitalization days in pediatric and adult units, respectively (p < 0.0001). Compared to inpatients with community-acquired ALRIs, those with nosocomial infections were more frequently adults (45.5% versus 2.6%, p = 0.0005) and subjects with at least one chronic complex condition (100.0% versus 41.0%, p < 0.0001). The total number of hospitalization days due to nosocomial ALRIs was higher in adults than in children (0.32% versus 0.11%, p < 0.0001).
Introduction

Respiratory syncytial virus (RSV) is associated with 19–81% of viral acute respiratory infections causing hospitalization in infants and children [1]. RSV also has a burden on healthcare services and winter mortality in older adults [2–4]. Published data on the epidemiology of nosocomial RSV infections are still limited. In infants, a severe course of nosocomial disease has been described, especially in subjects with comorbidities [5], even more severe than community-acquired RSV infections [6]. In adults, RSV acquisition seems to be frequently nosocomial or healthcare-related, with a higher mortality than with influenza virus infection [7]. However, to the best of our knowledge, no previous study compared the burden of community-acquired versus nosocomial RSV-associated acute lower respiratory tract infections (ALRIs) in both adult and pediatric patients concomitantly admitted at the same hospital.

Necker hospital (Paris) is a French 600 bed tertiary hospital, where large cohorts of adult and pediatric patients with chronic complex conditions (CCC) are regularly followed. A bundle of measures has been implemented to prevent nosocomial RSV-associated ALRIs, including implementation of droplet and contact precautions for symptomatic patients, annual education and training of all healthcare personnel, providing instructional materials for patients and visitors on recommended hand hygiene, respiratory hygiene/cough practices and limitation of pediatric visitors during seasonal outbreaks of viral ALRIs. Infants predisposed to developing severe RSV disease receive passive antiviral immunization with palivizumab in accordance to French guidelines [8]. Finally, our hospital has recently been partly rebuilt and includes now a high rate of single-patient rooms (91%), which may help to prevent healthcare-associated infections.

This study aims to compare the burden of nosocomial and community-acquired RSV-associated ALRIs in both adult and pediatric patients concomitantly admitted to the same hospital.

Patients and methods

Ethics

Participants provided informed consent for the anonymous use of their clinical and biological data for biomedical research (for paediatric patients, informed consent was provided by parents/guardians). This study was reviewed and approved by the Necker Hospital Institutional Review Board (registration number in the registry of the Assistance Publique – Hôpitaux de Paris: 20190729122906).

Conclusions: Nosocomial RSV-associated ALRIs rarely occurred, suggesting a good effectiveness of our infection control strategy. However, the burden of nosocomial infection was higher in adults than in children, suggesting that education and training of healthcare personnel, patients and visitors about the risk of nosocomial RSV infections should be reinforced in adult wards.

© 2020 The Authors. Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Statistical analysis

Categorical variables appear with their frequency distribution. Non-normally distributed continuous variables are expressed as the median and interquartile range. Chi-squared tests or Fisher’s exact tests were used to compare discrete variables, and the Wilcoxon rank test was used to compare continuous variables between patients with community-acquired versus nosocomial ALRIs. $P < 0.05$ was considered statistically significant.

Results

Community-acquired RSV-associated ALRIs requiring hospitalization: characteristics and burden

Between October 2018 and February 2019, 229 patients admitted to our hospital were diagnosed with community-acquired RSV-associated ALRIs. Their characteristics are summarized in Table 1. The majority were less than 6 months old (60.3%) and, among them, few were born preterm (18.8%). At least one CCC was present in 40.1% of subjects, most frequently a respiratory CCC. Viral and bacterial co-/supra-infections were documented in 17.5% and 5.7% of cases, respectively, but around one in two patients received antibiotics. The proportion of patients requiring ICU admission was high (40.1%) but only 3 patients (1.3%) died. All of them were children with severe cardiovascular ± respiratory CCC and died from acute respiratory distress syndrome.

When compared to all other patients admitted to our hospital during the same period of time, patients with community-acquired RSV infections accounted for 1.6% of inpatients and 3.1% of the total number of hospitalization days. The burden of community-acquired RSV infections was disproportionately higher in pediatric than in adult patients: 2.1% versus 0.2% of the total number of pediatric and adult inpatients, respectively ($P < 0.0001$); 4.2% versus 0.2% of the total number of hospitalization days in pediatric and adult units, respectively ($P < 0.0001$).

Among children with community-acquired RSV infections, palivizumab-based prophylaxis was given to 6/18 (33.3%), 6/6 (100%) and 4/4 (100%) of those for whom antiviral prophylaxis was recommended by the 1999 EMA, the 2007 French and the 2014 American guidelines, respectively.

Nosocomial RSV-associated ALRIs: characteristics and burden

Eleven patients were diagnosed with a possibly (n = 6) or definitely (n = 5) nosocomial RSV-associated ALRI (Table 1). Almost half of them (45.1%) were 60 years old or older. All subjects with nosocomial RSV infection had at least one CCC but none of them died from RSV.

Compared to inpatients with community-acquired RSV-associated ALRIs, those with nosocomial infections were more frequently adults ($P = 0.0005$) and subjects with at least one CCC ($P < 0.0001$). The rates of viral and bacterial co-/supra-infections, oxygen/ventilation requirement, ICU admissions, antibiotic treatments and deaths did not differ between inpatients diagnosed with community-acquired versus nosocomial infections. However, the length of stay was statistically longer in the latter than in the former ($P < 0.0001$).

When compared to all patients admitted to our hospital during the same period of time and free from community-acquired RSV-associated ALRIs, patients with nosocomial RSV ALRIs accounted for 0.08% of all inpatients and 0.17% of the total number of hospitalization days. The proportion of inpatients with nosocomial infections did not differ between children and adults (0.06% versus 0.15%, $P = 0.14$). However, the total number of hospitalization days due to nosocomial RSV-infected patients was higher in adults than in children (0.32% versus 0.11%, $P < 0.0001$).

No children with nosocomial RSV received palivizumab-based prophylaxis prior to the onset of their infection. Retrospectively, such prophylaxis was not recommended for any of these children by the EMA, the French or the American guidelines.

Discussion

To the best of our knowledge, we report one of the first studies evaluating the efficacy of the same bundle of infection control measures to prevent RSV ALRIs in both adult and pediatric patients admitted to the same tertiary hospital.

Some results regarding community-acquired RSV infections requiring hospitalization are in line with previous reports: most of the subjects hospitalized with RSV were aged ≤ 12 months, and especially ≤ 6 months [13–21]. The median length of hospital stay was in the range of that reported in previous pediatric studies (between 2 and 11 days). However, the prevalence of admission to ICU and the mortality rate were higher than previously described in high-income countries (41.0% versus 2–12%, and 1.3% versus < 0.5%, respectively) [1]. This could be explained by the high prevalence of CCC in the population of children followed in our tertiary hospital, and, consequently, in those admitted for community-acquired RSV infections. This proportion was higher than in previous studies, where typically > 70% of children hospitalized with RSV-related ALRI/bronchiolitis had no underlying medical conditions [16–18,22–24]. Thus, the epidemiological characteristics of patients admitted at our hospital with community-acquired RSV infections cannot be extrapolated to other French pediatric centers.

In our study, the burden of RSV among community-acquired ALRIs requiring hospitalization was strongly lower in adults compared to infants and children, despite the high prevalence of CCC (especially immunodeficiency) among adults followed in our center (data not shown). Our findings suggest that, although RSV has the potential to cause severe community-acquired ALRIs in high-risk adults (such as immunocompromised patients) [25], RSV infections seem to rarely require hospitalization in this population.

Few of our patients (2.6%) admitted with community-acquired infections received palivizumab-based antiviral prophylaxis prior to the onset of the infection. However, the retrospective evaluation of the medical files of all RSV-infected inpatients revealed that no other patient required palivizumab according to the 2007 French and the 2014 American guidelines [8,12]. Our results suggest that guidelines of antiviral prophylaxis are appropriately applied in our center but that most of
Table 1
Comparison of characteristics and follow-up of patients admitted at Necker Hospital (Paris, France) between October 2018 and February 2019 and presenting with community-acquired versus nosocomial RSV-associated ALRI

|                      | Total (n = 240) | Patients with community acquired RSV-associated ALRI (n = 229) | Patients with nosocomial RSV-associated ALRI (n = 11) | p       |
|----------------------|----------------|-----------------------------------------------------------------|------------------------------------------------------|---------|
| **Male sex (n, %)**  | 113 (47.1)     | 107 (46.7)                                                      | 6 (54.5)                                             | 0.61    |
| **Age (n, %)**       |                |                                                                |                                                      |         |
| 0–5 months           | 141 (58.8)     | 138 (60.3)                                                     | 3 (27.3)                                             | 0.0005  |
| including children born between 32 and 36 WOG | 23 | 23 | 0 |          |
| including children born < 32 WOG | 3 | 3 | 0 |          |
| 6–11 months          | 28 (11.7)      | 27 (11.8)                                                      | 1 (9.1)                                              |         |
| 12–23 months         | 23 (9.6)       | 23 (10.0)                                                      | 0 (0.0)                                              |         |
| 2–17 years           | 37 (15.4)      | 35 (15.3)                                                      | 2 (18.2)                                             |         |
| 18–59 years          | 4 (1.7)        | 4 (1.7)                                                        | 0 (0.0)                                              |         |
| ≥ 60 years           | 7 (2.9)        | 2 (0.9)                                                        | 5 (45.5)                                             |         |
| **Underlying medical conditions (n, %)** |              |                                                                |                                                      |         |
| At least one CCC     | 105 (43.8)     | 94 (41.0)                                                       | 11 (100.0)                                           | <0.0001 |
| Neuromuscular CCC    | 15 (6.3)       | 13 (5.7)                                                       | 2 (18.2)                                             |         |
| Cardiovascular CCC   | 24 (10.0)      | 21 (9.2)                                                       | 3 (27.3)                                             |         |
| Respiratory CCC      | 52 (21.7)      | 48 (21.0)                                                      | 4 (36.4)                                             |         |
| Renal CCC            | 11 (4.6)       | 7 (3.1)                                                        | 4 (36.4)                                             |         |
| Gastrointestinal CCC | 7 (2.9)        | 6 (2.6)                                                        | 1 (9.1)                                              |         |
| Hematological CCC and/or immune deficiency | 24 (10.0) | 18 (7.9) | 6 (54.5) |         |
| Metabolic CCC        | 2 (0.8)        | 2 (0.9)                                                        | 0 (0.0)                                              |         |
| Other congenital or genetic defect | 22 (9.2) | 21 (9.2) | 1 (9.1) |         |
| **Antiviral prophylaxis (n, %)** |              |                                                                |                                                      |         |
| palivizumab           | 6 (2.5)        | 6 (2.6)                                                        | 0 (0.0)                                              | 1.0     |
| i.v. or s.c. polyvalent | 3 (1.3)     | 3 (1.3)                                                        | 0 (0.0)                                              | 1.0     |
| immunoglobulin        |                |                                                                |                                                      |         |
| **Viral co-/super-infection (n, %)** |              |                                                                |                                                      |         |
| At least one virus    | 42 (17.5)      | 40 (17.5)                                                      | 2 (18.2)                                             | 1.0     |
| influenza virus       | 4              | 3                                                              | 1                                                    |         |
| parainfluenza virus   | 3              | 3                                                              | 0                                                    |         |
| rhinovirus            | 24             | 23                                                             | 1                                                    |         |
| adenovirus            | 4              | 4                                                              | 0                                                    |         |
| human metapneumovirus | 1              | 1                                                              | 0                                                    |         |
| coronavirus           | 11             | 10                                                             | 1                                                    |         |
| **Bacterial lower respiratory tract co-/super-infection** |              |                                                                |                                                      |         |
| Microbiologically proven infection | 14 (5.8) | 13 (5.7) | 1 (9.1) | 0.49    |
| Suspected infection   | 67 (27.9)      | 64 (27.9)                                                      | 3 (27.3)                                             | 1.0     |
| **Clinical follow-up** |              |                                                                |                                                      |         |
| LOS (days) (median, IQR) | 7 [5–10] | 7 [5–9] | 17 [11–26] | <0.0001 |
| ICU admission (n, %)  | 97 (40.4)      | 94 (41.0)                                                      | 3 (27.3)                                             | 0.53    |
| Oxygen requirement (n, %) | 189 (78.8) | 182 (79.5) | 7 (63.6) | 0.25    |
| Mechanical ventilation requirement (n, %) | 9 (3.8) | 8 (3.5) | 1 (9.1) | 0.35    |
| Non-invasive ventilation and/or high-flow nasal oxygen requirement (n, %) | 73 (30.4) | 72 (31.4) | 1 (9.1) | 0.18    |
| Antibiotic treatment (n, %) | 142 (59.2) | 137 (59.8) | 5 (45.5) | 0.36    |
| Death (n, %)          | 3 (1.3)        | 3 (1.3)                                                        | 0 (0.0)                                              | 1.0     |

RSV = respiratory syncytial virus; ALRI = acute lower respiratory tract infection; WOG = weeks of gestation; CCC = chronic complex conditions; i.v. = intravenous; s.c. = subcutaneous; LOS = length of stay; ICU = intensive care unit.

a For healthcare-associated infections, the length of stay after the diagnosis of RSV ALRI was described.
the patients admitted for RSV infections (and most of those admitted to pediatric ICU), did not fall into the recognized indications for RSV prophylaxis, as recently reported by Ghazaly et al. [26]. In light with the ongoing research into the development of new and more cost-effective strategies against RSV infections than palivizumab (including long acting monoclonal antibodies and vaccines), further larger studies defining the characteristics of patients hospitalized with severe RSV infections, may help to rethink the guidelines of RSV prophylactic strategies.

RSV is known to be a major nosocomial hazard on paediatric wards, especially in cases of age less than 5 months, prematurity and chronic lung disease of prematurity [6]. Previous studies described rates of nosocomial RSV infections between 0.4 and 9.6% [6,27–29], with poorer clinical outcomes than community-acquired RSV infections [6]. Contrasting with these results, we observed in our pediatric wards a low rate of nosocomial RSV-related ALRIs (0.06% of inpatients) and no death related to nosocomial RSV infection. This low rate of nosocomial infections could be related to our multifaceted infection control strategy including a high proportion of single-patient rooms (for both infected and uninfected patients), staff training repeated before each season of viral epidemics, screening of symptomatic patients, isolation/cohorting, hand washing, gloves and masks, gowns (for staff attending infants with respiratory symptoms) and restriction of visitors.

Interestingly, our study suggests that the efficacy of this infection control strategy may be less effective in adult than in pediatric wards. Indeed, nosocomial infections were proportionately more frequently diagnosed in adults than community-acquired RSV-related ALRIs (p < 0.0001) and the total number of hospitalization days due to nosocomial RSV infection was higher in adults than in children (0.32% versus 0.11%, p < 0.0001). Similarly, Kestler M et al. recently described that RSV acquisition was frequently nosocomial or healthcare-related in adults during flu season [7]. Although we did not observe the high RSV-related mortality described in adults by Kestler (14.7%), we described longer length of hospital stay in case of nosocomial versus community-acquired infections in adults. Our results suggest that, despite a low rate of nosocomial infections observed in adults (0.15% of inpatients), our multifaceted infection control strategy may be reinforced in adults wards in order to obtain similar results seen in pediatric units. Because of the low number of nosocomial infections during the 2018/2019 RSV epidemic, it could be interesting to repeat this study during several successive seasonal epidemics in order to evaluate the effectiveness of our bundle of measures in a larger population. This study has five main limitations. First, RSV-related ALRIs were defined from the data provided by the virology laboratory. Because RSV may not have been screened in a significant proportion of patients with ALRI, this study may underestimate the real burden of RSV infection in our center. This underestimation may be more pronounced in patients with mild symptoms (especially those with isolated upper respiratory tract infection), where RSV may have been less frequently screened than in case of severe infection. However this potential limitation does not hamper evaluation of the efficacy of our infection control strategy, which mainly aims to prevent severe infections. Second, although the ALRIs were primarily attributed to RSV by clinicians in all patients described in this study, we cannot exclude that viral and bacterial co-infections may have influenced their clinical outcome. This confounding factor cannot be excluded in our non intervention study because all other respiratory pathogens may not have been screened for. In order to evaluate the impact of this potential bias, further prospective studies are needed with systematic screening of all potential viral and bacterial co-infections. Third, this observational study does not allow the effectiveness of individual components of our multi-component control measures to be assessed. Similar observation was done by French CE et al. in the recent review of published and unpublished literature about the effectiveness of control measures to prevent nosocomial RSV transmission events [30]. However, because similar preventive strategies were applied in all units of our center, this limitation does not hamper the comparison of their efficacy on pediatric versus adult wards. Further studies are needed in order to evaluate to what extent the compliance with each measure of our infection control bundle differs between adult and paediatric populations. Because nosocomial infections may be transmitted by healthcare personnel, visitors and patients, it would be interesting to differentiate the compliance to measures targeting each of these populations in such further studies. Fourth, as previously discussed, the high prevalence of CCC among patients followed in our tertiary hospital hampers extrapolation of our results to other French hospitals. The higher prevalence of CCC among patients with nosocomial versus community-acquired RSV infections (100.0% versus 41.0%) may at least partly explain the longer length of stay in the former than in the latter. Fifth, we used a very large definition of a nosocomial case, by pooling “possibly” and “definitely” nosocomial infections. In previous studies investigating the risk of RSV transmission to patients and providing a clear definition of a nosocomial case, various cut-off were used to define it (mostly 5 days or more after hospital admission) [30]. Here, we chose a wider definition of a nosocomial case (i.e. infection occurring in a patient hospitalized continuously ≥ 2 days before the onset of respiratory symptoms), because (i) the RSV incubation period may be as short as 2 days [9], and (ii) we did not want to minimize the real burden of RSV nosocomial ALRIs. Interestingly, although we used such a wide cut-off, the burden was not high in our center. This limitation does not hamper comparison of the burden of nosocomial infections between pediatric and adult wards at our center.

Conclusions

In summary, the burden of community-acquired infections requiring hospitalization is disproportionately higher in infants/children than in adults admitted to our center. Nosocomial RSV-associated ALRIs rarely occurred, suggesting good efficacy of our multi-component preventive strategy. However, the burden of nosocomial infection was higher in adults than in children, suggesting that education and training of healthcare workers, patients and visitors about the risk of nosocomial respiratory viral disease should be reinforced on adult wards. The fact than > 97% of patients hospitalized with community-acquired or nosocomial RSV-associated ALRI were not
considered at "high-risk" (i.e. requiring immunoprophylaxis with palivizumab) according to the French and American guidelines, highlights the urgent need to develop new and more cost-effective antiviral preventive strategies, in order to decrease the burden of RSV infections requiring hospitalizations.

Acknowledgements

We thank all patients (and the parents/guardians of pediatric patients) who agreed to participate; the members of the Infection Control Unit (I. Le Guinche, P. Husson, S. Gotty, R. Beauvais, A. Métois) and the doctors, midwives, and personnel in the units of our center for their sustained efforts to prevent and monitor healthcare-associated infections.

Declaration of interest

P.F. has received research grants (to his institution) from the French National Agency for AIDS Research (ANRS) and honoraria and travel grants from ViVith Healthcare, Bristol-Myers Squibb, Janssen Cilag, Gilead Sciences, Pfizer, Medtronic and MSD France for participation in advisory boards, educational programs and conferences, outside the submitted work. M.L.-V. has received nonfinancial and other support from BioMérieux and nonfinancial support from Abbott and Ferring SAS, outside the submitted work. All other authors report no potential conflicts.

Funding source

This study was carried out as part of our routine work.

References

[1] Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther 2016;5:271–98. https://doi.org/10.1007/s40121-016-0123-0.
[2] McClure DL, Kieke BA, Sundaram ME, Simpson MD, Meece JK, Sifakis F, et al. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old. PLoS One 2014;9:e102586. https://doi.org/10.1371/journal.pone.0102586.
[3] Widmer K, Griffin MR, Zhu Y, Williams JV, Talbot HK. Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other Respir Viruses 2014;8:347–52. https://doi.org/10.1111/irv.12234.
[4] Reed C, Chaves SS, Daily Kirley P, Emerson R, Aragon D, Hancock EB, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One 2015;10:e0118369. https://doi.org/10.1371/journal.pone.0118369.
[5] Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009;94:99–103. https://doi.org/10.1136/adc.2008.139188.
[6] Simon A, Müller A, Khurana K, Engelhart S, Exner M, Schildgen O, et al. Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection: results from a prospective multicenter German surveillance study. Int J Hyg Environ Health 2008;211:241–50.
[7] Kestler M, Muñoz P, Mateos M, Adrados D, Bouza E. Respiratory syncytial virus burden among adults during flu season: an underestimated pathology. J Hosp Infect 2018;100:463–8. https://doi.org/10.1016/j.jhin.2018.03.034.
[8] Autorité de Santé Haute. Palivizumab. Avis de la Commission de la Transparence. 2007. accessed, https://www.has-sante.fr/upload/docs/evamed/CT-15884_SYNAGIS_OD_INS-Avis2_CT15884.pdf. [Accessed 9 December 2019].
[9] Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917–28.
[10] Feudtner C, Hays RM, Haynes G, Geyer JR, Neff JM, Koepsell TD. Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services. Pediatrics 2001;107:E99.
[11] European Medicines Agency. European public assessment report (EPAR) for Synagis. 2009. accessed, https://www.ema.europa.eu/en/human-medicines/human/EPAR/synagis. [Accessed 9 December 2019].
[12] American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus bronchiolitis. Pediatrics 2014;134:e620–38. https://doi.org/10.1542/peds.2014-1666.
[13] Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Hospitalization for respiratory syncytial virus in the paediatric population in Spain. Epidemiol Infect 2003;131:867–72.
[14] Fjaerli HO, Farstad T, Bratlie D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective study. BMC Pediatr 2004;4:25.
[15] Hervás D, Reina J, Yañez A, del Valle JM, Figuerola J, Hervás JA. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis 2012;31:1975–81. https://doi.org/10.1007/s10096-011-1529-y.
[16] Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 2013;132:e341–8. https://doi.org/10.1542/peds.2013-0303.
[17] García CG, Bhore R, Soriano-Fallas A, Trost M, Chason R, Ramilo O, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics 2010;126:e1453–60. https://doi.org/10.1542/peds.2010-0507.
[18] Resch B, Gussenleitner W, Mandl C, Müller W. Epidemiology of respiratory syncytial virus infection in Southern Austria. Pediatr Infect Dis J 2000;19:587–8.
[19] Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003;88:1065–9.
[20] Grimaldi M, Cornet B, Milou C, Gouyon JB. [Prospective regional study of an epidemic of respiratory syncytial virus (RSV) bronchiolitis]. Arch Pediatr 2002;9:572–80.
[21] Johnson JI, Ratard R. Respiratory syncytial virus-associated hospitalizations in Louisiana. J La State Med Soc 2012;164:268–73.
[22] Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360:588–98. https://doi.org/10.1056/NEJMoa0804877.
[23] Resch B, Gussenleitner W, Müller W. The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection 2002;30:193–7.
[24] Boyce TG, Mellen BG, Mitchell Jr EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000;137:865–70.
[25] Anderson NW, Binnicker MJ, Harris DM, Chirila RM, Brumble L, Mandrekar J, et al. Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective
[26] Ghazaly M, Nadel S. Characteristics of children admitted to intensive care with acute bronchiolitis. Eur J Pediatr 2018;177:913–20. https://doi.org/10.1007/s00431-018-3138-6.

[27] Kristensen K, Dahm T, Frederiksen PS, Ibsen J, Iyore E, Jensen AM, et al. Epidemiology of respiratory syncytial virus infection requiring hospitalization in East Denmark. Pediatr Infect Dis J 1998;17:996–1000.

[28] Berger A, Obweger E, Aberle SW, Langgartner M, Popow-Kraupp T. Nosocomial transmission of respiratory syncytial virus in neonatal intensive care and intermediate care units: a prospective epidemiologic study. Pediatr Infect Dis J 2010;29:669–70. https://doi.org/10.1097/INF.0b013e3181d76d61.

[29] Alan S, Erdeve O, Cakir U, Akduman H, Zenciroglu A, Akcakus M, et al. Outcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study. J Matern Fetal Neonatal Med 2016;29:2186–93. https://doi.org/10.3109/14767058.2015.1079614.

[30] French CE, McKenzie BC, Coope C, Rajanaidu S, Paranthaman K, Pebody R, et al. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. Influenza Other Respir Viruses 2016;10:268–90. https://doi.org/10.1111/irv.12379.